# DESCRIPTION

## FEDERALLY SPONSORED RESEARCH

- acknowledge government support

## BACKGROUND OF INVENTION

- introduce Usher syndrome
- limitations of current treatments

## SUMMARY

- introduce Usher 1F treatment limitations
- motivate gene addition therapy
- describe PCDH15 coding sequence limitations
- introduce first 5′ isolated nucleic acid
- define transgene composition
- specify promoter options
- describe splice donor composition
- specify PCDH15 protein origin
- describe Kozak sequence inclusion
- describe beta-actin exon and chimeric intron inclusion
- specify AAV ITRs
- introduce first 3′ isolated nucleic acid
- describe second portion of PCDH15 protein
- specify splice acceptor composition
- describe poly A tail inclusion
- describe WHP Posttranscriptional Regulatory Element inclusion
- describe tag inclusion
- describe detectable protein inclusion
- introduce second 5′ isolated nucleic acid
- describe recombinogenic sequence inclusion
- introduce second 3′ isolated nucleic acid
- describe recombinogenic sequence composition
- describe poly A tail composition
- describe WHP Posttranscriptional Regulatory Element composition
- summarize vector composition
- describe transgene components
- specify IRES or 2A peptide usage
- detail AAV ITRs and serotypes
- outline vector construction
- describe rAAV vector encoding PCDH15
- specify nucleotide sequence encoding detectable protein
- describe rAAV vector with recombinogenic sequence
- outline vector composition with tag
- describe vector with nucleotide sequence at least 80% identical to SEQ ID NOs: 22 or 23
- summarize first 5' rAAV composition
- describe first 3' rAAV composition
- summarize second 5' rAAV composition
- describe second 3' rAAV composition
- specify rAAV tropism for cells of the cochlea and/or the retina
- detail rAAV tropism for specific cell types
- describe AAV capsid protein variants
- summarize PCDH15 expression system composition
- describe host cell composition
- outline pharmaceutical composition
- describe method for expressing full-length PCDH15
- outline method for treating hearing loss
- outline method for treating vision loss
- outline method for treating Usher Syndrome, Type 1F
- specify subject as mammal
- specify subject as human or non-human mammal
- describe hearing loss and/or vision loss associated with Usher syndrome type 1F
- describe mutation in the PCDH15 gene
- specify administration results in expression of full-length PCDH15 protein
- describe administration results in expression of full-length PCDH15 protein in specific cells
- describe administration via injection
- specify injection location

## DETAILED DESCRIPTION

- introduce genetic diseases
- motivate gene therapy approach
- describe limitations of AAV vectors
- propose dual rAAV solution

### I. Dual-AAV Vector System Encoding Full-Length PCDH15

- introduce dual-AAV vector system
- describe system components
- define nucleic acid sequence
- explain isolated nucleic acid
- describe PCDH15 gene structure
- introduce PCDH15 protein function
- provide exemplary amino acid sequences
- describe dual-AAV vector system formation
- explain trans splicing mechanism
- describe homologous recombination and splicing
- introduce 5' isolated nucleic acid
- introduce 3' isolated nucleic acid
- describe promoter operably linked to transgene
- explain recombinogenic sequence
- describe splice donor and acceptor
- explain RNA splicing mechanism
- describe full-length PCDH15 expression
- introduce human PCDH15 full-length amino acid sequences
- describe CD1 splice form of PCDH15
- describe CD2 splice form of PCDH15
- describe CD3 splice form of PCDH15
- explain split site of PCDH15 coding sequence
- describe exons of PCDH15 gene
- introduce codons of PCDH15 coding sequence
- describe split site between codons 1168 and 1169
- describe split site between codons 1161 and 1162
- describe split site between codons 1156 and 1157
- explain N-terminal portion of PCDH15 protein
- describe nucleotide sequence encoding first portion of PCDH15
- introduce promoter operably linked to nucleic acid sequence
- explain operably linked regulatory sequences
- describe constitutive promoter
- introduce hybrid cytomegalovirus (CMV) immediate-early/Chicken beta-actin promoter
- introduce chicken beta-actin (CBA) promoter
- describe minimal promoter
- introduce minimal CMV promoter
- introduce JeT promoter
- introduce human EF1-α core promoter
- describe promoter nucleotide sequence
- provide exemplary mini-CMV promoter nucleotide sequence
- describe dual-AAV vector system advantages
- explain gene therapy applications
- conclude dual-AAV vector system description
- introduce dual-AAV vector system
- describe human EF1-ca promoter sequence
- discuss inducible promoters
- list examples of inducible promoters
- describe native promoter usage
- discuss native expression control elements
- list examples of native promoters
- describe ProA6 promoter
- discuss tissue-specific regulatory sequences
- list examples of eye-specific promoters
- list examples of inner ear cell-specific promoters
- describe 3' isolated nucleic acid encoding PCDH15
- discuss CD1, CD2, or CD3 splice forms of PCDH15
- describe splicing donor and acceptor
- discuss recombinogenic sequence
- describe detectable protein
- list examples of detectable proteins
- discuss IRES sequence
- describe self-cleavage peptide
- discuss Foot and Mouth Disease Virus 2A sequence
- describe IRES and eGFP sequence
- discuss polyadenylation sequence
- describe SV40 poly A sequence
- describe BGH poly A sequence
- discuss 5' isolated nucleic acid encoding PCDH15
- describe promoter and regulatory elements
- discuss tissue-specific expression
- describe 3' isolated nucleic acid encoding detectable protein
- discuss IRES and self-cleavage peptide
- describe polyprotein and cleavage
- discuss polyadenylation and transcription termination
- conclude dual-AAV vector system
- introduce dual-AAV vector system
- describe protein tag options
- describe vector elements
- define sequence identity
- describe ITR sequences
- describe AAV ITR serotypes
- describe second ITR region
- describe mutant ITR lacking TRS
- introduce 5' and 3' isolated nucleic acids
- describe regulatory elements
- describe WPRE and polyadenylation signals
- describe exemplary dual-AAV vectors
- describe rAAV vector encoding first portion of PCDH15
- describe rAAV vector encoding second portion of PCDH15
- describe nucleotide sequence identity
- describe rAAV vector with IRES or 2A peptide
- describe rAAV vector with tag
- describe rAAV vector with HA tag
- describe rAAV vector with C-terminal tag
- introduce recombinant AAV for delivering full-length PCDH15
- describe first 5' rAAV
- describe AAV capsid protein
- describe first 5' isolated nucleic acid
- describe 5' ITR
- describe CMV enhancer and promoter
- describe Kozak sequence
- describe nucleotide sequence encoding first portion of PCDH15
- describe splice donor
- describe 3' ITR
- describe second 5' rAAV
- describe second 5' isolated nucleic acid
- describe second ITR region
- conclude dual-AAV vector system
- define dual-AAV vector system
- describe first 3' rAAV
- describe first 5' rAAV
- describe second 3' rAAV
- describe second 5' rAAV
- define isolated AAVs
- describe recombinant AAV production
- describe AAV capsid proteins
- describe AAV serotypes
- describe AAV-S capsid protein
- describe AAV-S transduction efficiency
- describe conservative amino acid substitutions
- describe PCDH15 expression system
- describe co-delivery of rAAVs
- describe rAAV delivery to mammal
- describe rAAV delivery to ear
- describe rAAV delivery to eye
- describe target cells
- describe host cell containing nucleic acid or rAAV
- describe genetic element delivery
- describe rAAV vector construction
- describe rep sequences
- describe cap sequences
- describe helper functions
- describe packaging host cell
- describe genetic engineering
- describe recombinant engineering
- describe synthetic techniques
- describe rAAV production methods
- describe triple transfection method
- describe AAV helper function vector
- describe accessory function vector
- describe transfected host cells
- describe transfection techniques
- describe host cell definition
- describe cell line definition
- describe recombinant cell definition
- describe vector definition
- describe promoter definition
- describe operatively positioned definition
- describe expression vector definition
- describe packaging methods
- describe other suitable methods

### III. Pharmaceutical Composition for Delivering Transgenes to the Ear and Eye

- describe rAAV delivery methods
- introduce pharmaceutical composition
- describe rAAV administration routes
- specify mammalian subjects
- describe ear injection methods
- describe eye injection methods
- introduce pharmaceutically acceptable carriers
- list exemplary carriers
- describe buffering agents
- list exemplary buffering agents
- introduce additional pharmaceutical ingredients
- list exemplary preservatives
- list exemplary chemical stabilizers
- introduce surfactants
- list exemplary surfactants
- describe rAAV administration amounts
- describe gene transfer and expression
- list exemplary administration routes
- describe dose determination factors
- describe effective amounts of rAAV
- describe dosage ranges
- describe administration frequencies
- describe formulation to reduce aggregation
- describe development of dosing regimens
- describe pharmaceutical formulation considerations
- describe direct delivery to target tissue
- describe alternative administration routes
- describe injectable pharmaceutical forms
- describe sterile aqueous solutions
- describe sterile powders
- describe salt forms of rAAV
- describe carriers and media
- describe delivery vehicles
- describe liposome formulations
- describe nanocapsule formulations

### IV. Therapeutic Applications

- introduce therapeutic applications
- specify subject of treatment
- describe hearing loss and/or blindness
- motivate Usher Syndrome type 1F
- define mutation in PCDH15 gene
- describe methods for making mutations
- summarize gene therapy
- describe delivery of functional gene product
- motivate protein-encoding transgenes
- describe treatment of Usher syndrome, Type 1F
- outline methods for delivering transgene
- describe administration of isolated nucleic acids
- specify effective amount of rAAV
- describe mode of administration
- motivate efficient transduction of cochlear cells
- describe treatment of hereditary hearing loss and/or vision loss
- specify administration to patients
- describe combination therapy
- conclude with incorporation of references

## EXAMPLES

### Example 1. Dual AAV Vectors for Delivering Full-Length PCDH15 in Hair Cells and Retina Cells

- motivate Usher syndrome type 1F
- describe hearing loss and gene therapy
- introduce PCDH15 protein and its role in hair cells
- describe structure of PCDH15 protein
- motivate dual vector AAV delivery
- describe trans-splicing and hybrid methods
- illustrate vector maps of AAV vector 1 and vector 2
- describe packaging of dual vectors in AAV9-PHP.B capsid
- test expression of full-length PCDH15 in HEK cells
- evaluate proper membrane targeting of PCDH15
- test expression of PCDH15 and rescue of function in knockout mice
- evaluate expression and localization of full-length PCDH15 in hair cells
- test rescue of hair-cell development
- test hair-cell mechanotransduction
- test hearing of injected mice
- test vestibular function
- describe production of dual AAV vectors for PCDH15 and HA tag
- test expression and localization of full-length PCDH15 in hair cells
- test rescue of mechanotransduction
- test rescue of hearing and balance
- describe electron microscopy results
- motivate dual vector AAV delivery in the eye
- test rescue of visual pathology in the mouse retina
- describe AAV capsids and promoters for photoreceptors
- test expression and localization of PCDH15 protein in photoreceptors
- test functional rescue by measuring the electroretinogram
- describe zebrafish model for Usher 1F
- test rescue of function in zebrafish retinas
- describe non-human primate model for Usher 1F
- test PCDH15 expression and localization in photoreceptor cells
- evaluate toxicity by ERG and histopathology
- describe subretinal injections of AAVs encoding epitope-tagged PCDH15
- evaluate protein expression and localization to calyceal processes

### Example 2. Morphological Hair Bundle Rescue in Pcdh15 Conditional Knockout Mice

- describe morphological hair bundle rescue

### Example 3. HA-Tagged PCDH15 Trafficking to the Stereocilia

- test HA-tagged PCDH15 trafficking to the stereocilia

### Example 4. Hearing Rescue Using Dual Vectors Encoding PCDH15 or HA-PCDH15

- test hearing rescue using dual vectors encoding PCDH15 or HA-PCDH15

### Other Embodiments

- describe alternative features and modifications

## EQUIVALENTS

- acknowledge variations of embodiments
- emphasize exemplary nature of parameters
- recognize equivalents to embodiments
- define scope of inventive embodiments
- clarify individual features and combinations
- control definitions over dictionary meanings
- incorporate references by citation
- define "a" and "an" as "at least one"
- define "and/or" as "either or both"
- define "or" as inclusive
- clarify "at least one" and "consisting essentially of"

